Cheryl Mcdonald

发表

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

D. Dieterich, S. Henn, M. Ramgopal, 2015, The New England journal of medicine.

Cobicistat-Boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment

F. Post, M. Ramgopal, M. Fisher, 2014, HIV clinical trials.

Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.

G. Moyle, D. Butcher, Wenhua Hu, 2012, AIDS patient care and STDs.

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens

M. Ramgopal, A. Luetkemeyer, R. Bhore, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment Week 144 Results

P. Sax, M. Das, A. Clarke, 2017, Journal of acquired immune deficiency syndromes.

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

C. del Rio, L. Lam, C. Libertin, 2021, The Lancet Respiratory Medicine.

A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

M. Kozal, R. Leavitt, F. Raffi, 2012, HIV clinical trials.

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

M. Das, J. Lelièvre, J. Slim, 2019, The lancet. HIV.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

Impact of Switching Virologically Suppressed, HIV-1-Infected Patients from Twice-Daily Fixed-Dose Zidovudine/Lamivudine to Once-Daily Fixed-Dose Tenofovir Disoproxil Fumarate/Emtricitabine

R. Ebrahimi, P. Ruane, E. Dejesus, 2008, HIV Clinical Trials.

Clinical targeting of HIV capsid protein with a long-acting small molecule

J. R. Somoza, W. Sundquist, Xiaohong Liu, 2020, Nature.

Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen (STR): Week 48 Data in HIV-1-Infected Virologically Suppressed Adults

A. Lazzarin, A. Rachlis, A. Cheng, 2015 .

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

M. Saag, M. Das, J. Flamm, 2015, Journal of Acquired Immune Deficiency Syndromes.

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor

M. Ramgopal, G. Moyle, M. Fisher, 2014, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study

M. Saag, M. Ramgopal, D. Brainard, 2021, Journal of acquired immune deficiency syndromes.

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.

J. Baeten, Samir K. Gupta, M. Ramgopal, 2023, The lancet. HIV.

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study

C. Mussini, C. Spinner, E. Y. Wong, 2019, HIV research & clinical practice.